Paul Hudson, CEO of Sanofi, discusses the use of artificial intelligence (AI) technology in the company's operations. Sanofi is focused on discovering new medicines and improving organisational efficiency through AI. The company uses advanced language models and partnerships with companies such as OpenAI and Formation Bio to customise these models for drug discovery.
Hudson stresses that Sanofi is not a coding company, but a drug discovery and development company. The collaboration with OpenAI and Formation Bio makes it possible to customise language models to treat previously incurable diseases. Sanofi is focusing on using AI to amplify the effectiveness of its employees rather than downsizing.
Sanofi recently won approval in Europe for an advanced treatment for chronic obstructive pulmonary disease (COPD), reducing hospital admissions by 30%. The company aspires to become the global leader in immunology and is banking on AI to improve its decision-making and scientific capabilities.
Hudson mentions that Sanofi is selling parts of its business to focus on drug research and development. The company plans to separate its consumer business by the fourth quarter of 2024, exploring various options including an IPO or sale.


Bloomberg TV provided by MT Newswires

Bloomberg videos, provided by MT Newswires